Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Bone marrow examination or peripheral blood analysis confirming active acute myeloid leukemia by WHO criteria~  * No M3 acute myeloid leukemia~* Not a candidate for allogenic bone marrow transplantation~* Patient must be in first relapse after having received induction chemotherapy~  * Received 1 or 2 courses with remission lasting at least 1 month~* Patients with chloromas or leukemia cutis are eligible~* No evidence of leptomeningeal involvement~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2~* Liver enzymes (total bilirubin, aspartate aminotransferase (AST) and ALT) ≤ 2.5 times the upper limits of normal~  * Liver enzymes ≥ 2.5 are acceptable if physician documents that it is secondary to the disease~* Serum creatinine ≤ 3 mg/dL~* No poorly controlled medical conditions that would seriously complicate compliance with this study~* No other active primary malignancy other than carcinoma in situ of the cervix or basal cell carcinoma of the skin~* No New York Heart Association grade III or IV cardiac problems, defined as congestive heart failure or myocardial infarction within 6 months prior to start of study~* Pregnant or nursing women are ineligible~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after study participation~* No documented history of human immunodeficiency virus (HIV) infection~* No history of chronic liver disease~* Ejection fraction ≥ 45%~* No significant history of non-compliance to medical regimens or inability to give reliable informed consent~PRIOR CONCURRENT THERAPY:~* Previous treatment related toxicities should be resolved to grade 1 or better~* No other investigational agents within 14 days prior to the start of study~* No chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to start of study~* No major surgery within 2 weeks prior to start of study~* At least two weeks must have elapsed since the conclusion of radiation therapy and the start of gemcitabine hydrochloride, provided the acute effects of radiation treatment have been resolved

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine + Mitoxantrone (Type: EXPERIMENTAL): Gemcitabine Hydrochloride as administered as a continuous intravenous infusion (I.V.) at 10mg/m\^2/minute for 12 hours, starting on Day 1. Mitoxantrone Hydrochloride was given at a dose of 12mg/m\^2/day I.V. on days 1, 2, and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).